A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with relapsed/refractory acute myeloid leukemia (AML).
Karen W. L. Yee
No relevant relationships to disclose
Michael Savona
No relevant relationships to disclose
Morten Sorensen
Research Funding - Karyopharm Therapeutics
Peter Brown
No relevant relationships to disclose
William G. Blum
No relevant relationships to disclose
Daniel J. DeAngelo
No relevant relationships to disclose
Martin Gutierrez
No relevant relationships to disclose
Ramiro Garzon
Employment or Leadership Position - Ohio State University
Consultant or Advisory Role - Guidepoint Global
Research Funding - Karyopharm Therapeutics
Andre C. Schuh
No relevant relationships to disclose
Nashat Y. Gabrail
No relevant relationships to disclose
Martha Wadleigh
No relevant relationships to disclose
Jeffrey E. Lancet
No relevant relationships to disclose
Bijal D. Shah
No relevant relationships to disclose
Jesus G. Berdeja
No relevant relationships to disclose
Nina D. Wagner-Johnston
No relevant relationships to disclose
Ian Flinn
No relevant relationships to disclose
Tami Rashal
Consultant or Advisory Role - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Michael Kauffman
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Sharon Shacham
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Richard M. Stone
No relevant relationships to disclose